Ocular viral infections

Most frequent adverse reactions -were mild -,
 transcient burning or stinging upon instillation 4%, palpebral edema 2%,

Other adverse reactions-
superficial punctuate, keratopathy, epithelial keratapathy, hypersensitivity reactions,
stromal edema, irritation, hyperremia, and increased ontraocular pressure

Hyprsensitivity to the drug or  the ingredients in the formulation

Special Precautions/ Warnings-

Diagnosis - only prescribe trifluridine solution for patients who have clinical diagnosis of
herpetic keratitis

Irritation- trifluridine may cause mild local irritation of the conjuntiva  ad cornea when instilled, but are transcient effects

Resistence - although not well documented, possibility of development of viral resistence on multiple exposure to trifluridine

Pregnancy - trifluridine ophthalmic solution should be used during pregnancy only if the potential benefits justifies the potential risk to the fetus.

Lactation- the drug should be be prescribed for nursing mothers unless the potential benefits outweigh the potential risks.

Children- safety and efficacy in pediatric patients below 6 years of age have not been established

Indication-

Ocular viral infections

Dosage-
Instil 1 drop of trifluridine ophthalmic solution onto the cornea of the affected eye every 2 hours while awake for a maximum daily dosage of 9 drops until the corneal ulcer has completely re-epithelialized.

Following re-epithelialization treatment for an additional 7 days of 1 drop every  4 hours while awake for a maximum daily dosage of 5 drops is recommended.

If there are no signs of improvement after 7 days of therapy or complete re-epitheliazation  
has not occured after 14 days of therapy, other forms of therapy should be considered.

Storage under refrigeration 2 to 8C ( 36 to 46F)

1. Only prescribe trifluridine solution for patients who have clinical diagnosis of
herpetic keratitis

2. Irritation- trifluridine may cause mild local irritation of the conjuntiva  ad cornea when instilled,  but are transcient effects

3. Resistence- Although not well documented, possibility of development of viral resistence on  multiple erposure to trifluridine

4. Pregnancy - trifluridine ophthalmic solution should be used during pregnancy only if the potential    benefits justifies the potential risk to the fetus.

5. Lactation- the drug should be be prescribed for nursing mothers unless the potential benefits  outweigh the potential risks.

6. Children- safety and efficacy in pediatric patients below 6 years of age have not been established

Pregnancy -

Ttrifluridine ophthalmic solution should be used during pregnancy only if the potential
benefits justifies the potential risk to the fetus.

Lactation-

The drug should be be prescribed for nursing mothers unless the potential benefits
outweigh the potential risks.

Children-

Safety and efficacy in pediatric patients below 6 years of age have not been established